^
    3ms
    BMX-001 acts as a selective chemoradioprotector in rectal cancer. (PubMed, Redox Biochem Chem)
    We also found that BMX-001 with 5-FU treatment enhanced DPYD sulfenylation, a protein known to detoxify 5-FU, and ALDH7A1 sulfenylation, a protein known to detoxify aldehydes. Together, these results suggest that BMX-001 can protect against oxidative stress in normal tissue via Nrf2 dependent and independent mechanisms.
    Journal
    |
    NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • DPYD (Dihydropyrimidine Dehydrogenase) • ALDH7A1 (Aldehyde Dehydrogenase 7 Family Member A1) • CAT (Catalase)
    |
    5-fluorouracil • BMX-001
    4ms
    Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, University of Nebraska | Trial primary completion date: Jul 2026 --> Oct 2026
    Trial primary completion date
    |
    5-fluorouracil • mitomycin • BMX-001
    8ms
    Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, University of Nebraska | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date
    |
    5-fluorouracil • mitomycin • BMX-001
    over1year
    NRG-CC013: Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer (clinicaltrials.gov)
    P2, N=98, Recruiting, NRG Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • BMX-001
    over1year
    BMX-HGG: Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 (clinicaltrials.gov)
    P1/2, N=177, Completed, BioMimetix JV, LLC | Active, not recruiting --> Completed | Phase classification: P2 --> P1/2
    Trial completion • Phase classification
    |
    temozolomide • BMX-001
    over1year
    Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, University of Nebraska | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    5-fluorouracil • mitomycin • BMX-001
    almost2years
    Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer (clinicaltrials.gov)
    P2, N=98, Not yet recruiting, NRG Oncology | Trial completion date: Sep 2026 --> Jan 2027 | Initiation date: Oct 2024 --> Apr 2025 | Trial primary completion date: Sep 2026 --> Jan 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    cisplatin • BMX-001
    almost2years
    BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer (clinicaltrials.gov)
    P1/2, N=27, Not yet recruiting, BioMimetix JV, LLC
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    paclitaxel • BMX-001
    2years
    Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer (clinicaltrials.gov)
    P2, N=98, Not yet recruiting, NRG Oncology
    New P2 trial
    |
    cisplatin • BMX-001
    over2years
    Single-Cell Profiling Reveals Immune-Based Mechanisms Underlying Tumor Radiosensitization by a Novel Mn Porphyrin Clinical Candidate, MnTnBuOE-2-PyP5+ (BMX-001). (PubMed, Antioxidants (Basel))
    CellChat analysis showed that the number of cell-cell communications was the lowest in the MnBuOE/RT group. Our study is the first to provide evidence for the combined radiotherapy with a novel Mn porphyrin clinical candidate, BMX-001, from the perspective of each cell type within the tumor microenvironment.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    BMX-001
    over2years
    BMX-HGG: Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, BioMimetix JV, LLC | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Aug 2023
    Trial completion date • Trial primary completion date
    |
    temozolomide • BMX-001
    over2years
    A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy (clinicaltrials.gov)
    P1/2, N=35, Terminated, BioMimetix JV, LLC | N=69 --> 35 | Trial completion date: Sep 2025 --> Apr 2024 | Recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Dec 2023; Cessation of grant funding
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    BMX-001